Moderna, Inc.
MRNAAPI behind this page
MRNA FY 2025 request
Playground key active
/api/financials?ticker=MRNA&year=2025&quarter=4&full_year_mode=true
Pick an endpoint and run the request.Income Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Revenue | 1,944 | 3,236 | -39.9% |
Show Product Lines breakouts |
|||
| Collaboration Arrangement Including Arrangements With Affiliate [Member] | 13 | 48 | -72.9% |
| Collaboration Arrangement Including Arrangements With Affiliate [Member] · Vertex | 13 | 23 | -43.5% |
| COVID | 1,810 | 3,084 | -41.3% |
| Grant | 22 | 37 | -40.5% |
| Grant · BARDA | 9 | 34 | -73.5% |
| Grant · Other grant revenue | 13 | 3 | +333.3% |
| Licensing and royalty revenue | 11 | 42 | -73.8% |
| Net product sales | 1,818 | 3,109 | -41.5% |
| Net product sales · Europe | 50 | 573 | -91.3% |
| Net product sales · Rest of world | 603 | 810 | -25.6% |
| Net product sales · US | 1,165 | 1,726 | -32.5% |
| Product And Service Other | 126 | 127 | -0.8% |
| RSV | 8 | 25 | -68.0% |
| Stand-ready manufacturing revenue | 80 | — | — |
Show Geography breakouts |
|||
| Europe | 53 | 598 | -91.1% |
| Rest of world | 692 | 853 | -18.9% |
| US | 1,199 | 1,785 | -32.8% |
| Cost of Revenue | 868 | 1,464 | -40.7% |
| Research & Development | 3,132 | 4,543 | -31.1% |
Show Counterparty Name breakouts |
|||
| Blackstone Life Sciences (Blackstone) · Collaborative Arrangement Transaction With Party To Collaborative Arrangement | 340 | 267 | +27.3% |
| Merck · Collaborative Arrangement Transaction With Party To Collaborative Arrangement | 407 | 390 | +4.4% |
| General & Administrative | 1,018 | 1,174 | -13.3% |
| Total Costs & Expenses | 5,018 | 7,181 | -30.1% |
| Operating Income | -3,074 | -3,945 | +22.1% |
| Interest Income | 314 | 425 | -26.1% |
| Other Non-Operating Income (Expense) | -8 | -87 | +90.8% |
| Income Before Taxes | -2,768 | -3,607 | +23.3% |
| Income Tax Expense (Benefit) | 54 | -46 | +217.4% |
| Net Income | -2,822 | -3,561 | +20.8% |
Show Equity Components breakouts |
|||
| Retained Earnings | -2,822 | -3,561 | +20.8% |
| EPS (Basic) | -7.26 | -9.28 | +21.8% |
| EPS (Diluted) | -7.26 | -9.28 | +21.8% |
| Wtd Avg Shares (Basic) | 389 | 384 | +1.3% |
| Wtd Avg Shares (Diluted) | 389 | 384 | +1.3% |
| Comprehensive Income | -2,767 | -3,448 | +19.8% |
| Other Comprehensive Income | 55 | 113 | -51.3% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | 16 | -3 | +633.3% |
| Accumulated Net Unrealized Investment Gain Loss | 28 | 124 | -77.4% |
| Accumulated Other Comprehensive Income | 55 | 113 | -51.3% |
| Accumulated Translation Adjustment | 11 | -8 | +237.5% |
Balance Sheet
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 2,595 | 1,927 | +34.7% |
| Available For Sale Securities Debt Securities Current | 3,204 | 5,098 | -37.2% |
| Accounts Receivable | 184 | 358 | -48.6% |
| Inventory | 153 | 117 | +30.8% |
| Prepaid Expenses & Other Current Assets | 408 | 599 | -31.9% |
| Total Current Assets | 6,544 | 8,099 | -19.2% |
| Non-Current Assets | |||
| Available For Sale Securities Debt Securities Noncurrent | 2,336 | 2,494 | -6.3% |
| Operating Lease Right-of-Use Assets | 719 | 759 | -5.3% |
| Other Non-Current Assets | 605 | 594 | +1.9% |
| Total Assets | 12,338 | 14,142 | -12.8% |
| Goodwill | 52 | 52 | 0.0% |
| Intangible Assets | 45 | 40 | +12.5% |
| Deferred Tax Assets | 81 | 81 | 0.0% |
| Other Assets | |||
| Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | 2,134 | 2,196 | -2.8% |
Show Geography breakouts |
|||
| Europe | 303 | 283 | +7.1% |
| Rest of world | 363 | 381 | -4.7% |
| US | 1,468 | 1,532 | -4.2% |
| Current Liabilities | |||
| Accounts Payable | 317 | 405 | -21.7% |
| Accrued Liabilities | 1,386 | 1,427 | -2.9% |
| Deferred Revenue (Current) | 99 | 153 | -35.3% |
| Other Liabilities Current | 185 | 221 | -16.3% |
| Total Current Liabilities | 1,987 | 2,206 | -9.9% |
| Non-Current Liabilities | |||
| Contract With Customer Liability Noncurrent | 153 | 58 | +163.8% |
| Operating Lease Liabilities | 653 | 671 | -2.7% |
| Finance Lease Liability Noncurrent | 20 | 39 | -48.7% |
| Long-Term Debt | 590 | — | — |
| Other Non-Current Liabilities | 285 | 267 | +6.7% |
| Total Liabilities | 3,688 | 3,241 | +13.8% |
| Long-Term Debt (Q) | — | — | — |
Show Debt Instrument breakouts |
|||
| Initial Term Loan · Secured Debt | 590 | — | — |
| Deferred Tax Liabilities | 249 | 231 | +7.8% |
| Stockholders' Equity | |||
| Additional Paid-In Capital | 1,382 | 866 | +59.6% |
| Accumulated Other Comprehensive Income | 45 | -10 | +550.0% |
| Retained Earnings | 7,223 | 10,045 | -28.1% |
| Total Stockholders' Equity | 8,650 | 10,901 | -20.6% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | 4 | -12 | +133.3% |
| Accumulated Net Unrealized Investment Gain Loss | 38 | 10 | +280.0% |
| Accumulated Other Comprehensive Income | 45 | -10 | +550.0% |
| Accumulated Translation Adjustment | 3 | -8 | +137.5% |
| Additional Paid In Capital | 1,382 | 866 | +59.6% |
| Retained Earnings | 7,223 | 10,045 | -28.1% |
| Total Liabilities & Equity | 12,338 | 14,142 | -12.8% |
Cash Flow Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Stock-Based Compensation | 483 | 429 | +12.6% |
| Other Depreciation And Amortization | 215 | 189 | +13.8% |
| Investment Income Net Amortization Of Discount And Premium | -67 | -95 | +29.5% |
| Income Loss From Equity Method Investments Net Of Dividends Or Distributions | 8 | 52 | -84.6% |
| Other Non-Cash Items | 77 | 60 | +28.3% |
| Change in Accounts Receivable | 156 | 534 | -70.8% |
| Change in Prepaid & Other Assets | 153 | 145 | +5.5% |
| Change in Inventory | -34 | 83 | -141.0% |
| Increase Decrease In Right Of Use Asset Operating Leases | 38 | -53 | +171.7% |
| Change in Accounts Payable | -92 | -69 | -33.3% |
| Increase Decrease In Accrued Liabilities | -2 | -385 | +99.5% |
| Change in Deferred Revenue | 41 | -439 | +109.3% |
| Increase Decrease In Operating Lease Liability | -21 | 28 | -175.0% |
| Increase Decrease In Other Operating Liabilities | -6 | 78 | -107.7% |
| Net Cash from Operations | -1,873 | -3,004 | +37.6% |
| Depreciation & Amortization | 211 | 185 | +14.1% |
| Deferred Income Taxes | 10 | -1 | +1100.0% |
| Investing Activities | |||
| Purchases of Investments | -5,768 | -6,529 | +11.7% |
| Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities | 5,563 | 5,562 | 0.0% |
| Proceeds From Sale Of Available For Sale Securities Debt | 2,353 | 3,967 | -40.7% |
| Capital Expenditures | -192 | -1,051 | +81.7% |
| Payments To Acquire Intangible Assets | -10 | — | — |
| Net Cash from Investing | 1,946 | 1,949 | -0.2% |
| Financing Activities | |||
| Proceeds From Lines Of Credit | 600 | — | — |
| Debt Issuance Costs | -22 | — | — |
| Proceeds From Stock Plans | 35 | 66 | -47.0% |
| Share Repurchases | -2 | — | — |
| Finance Lease Principal Payments Net Of Adjustments | -18 | -10 | -80.0% |
| Net Cash from Financing | 593 | 56 | +958.9% |
| Supplemental | |||
| Income Taxes Paid | 26 | 197 | -86.8% |
| Interest Paid | 10 | 24 | -58.3% |
| Unpaid Capital Expenditures | 83 | 97 | -14.4% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 2 | — | — |
| Net Change in Cash | 668 | -999 | +166.9% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 2,597 | 1,929 | +34.6% |
Values in millions USD. Source: SEC EDGAR 10-K filing.